VAERS Explorer
Back to explore

Report #2870441

Received Nov 4, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
0.3 yrs
State
NJ
Recovered
Unknown
Vaccinated
Oct 21, 2025
Onset
Oct 21, 2025
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
DTAPIPVHIBDTAP + IPV + HIB (PENTACEL)SANOFI PASTEURUNKUK364AAOT

Symptoms (2)

No adverse eventProduct preparation issue

Symptom narrative

gave only the liquid part of PENTACEL with no reported adverse event; Initial information received on 22-Oct-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 4 months old male patient who was administered of only the liquid part of Diphtheria/Tetanus/5 Hybrid Ac Pertussis/Ipv(Vero)/Hib(Prp/T) Vaccine [Pentacel (Vero)], with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 21-Oct-2025, the patient received, only the liquid part of suspect Diphtheria/Tetanus/5 Hybrid Ac Pertussis/Ipv(Vero)/Hib(Prp/T) Vaccine (once), Suspension for injection (Strength standard) lot UK364AA and expiry date 31-Mar-2027 via unknown route in unknown administration site for immunisation, with no reported adverse event (single component of a two-component product administered) (Latency Same day). Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.; Sender's Comments: US-SA-2025SA317337: